Context: In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, identified mevastatin (ML-236B), a molecule produced by the fungus Penicillium citrinum, as an inhibitor of HMG-CoA reductase, a critical enzyme used by the body to produce cholesterol. Animal trials showed very good inhibitory effect as in clinical trials, however a long term study in dogs found toxic effects at higher doses and as a result mevastatin was believed to be too toxic for human use. Mevastatin was never marketed, because of its adverse effects of tumors, muscle deterioration, and sometimes death in laboratory dogs.

Question: Why was Mevastatin never marketed?
Answer: adverse effects of tumors, muscle deterioration, and sometimes death

Question: Who discovered Mevastatin?
Answer: Akira Endo

Question: What is HMG-CoA responsible for producing?
Answer: cholesterol

Question: Where did Endo discover ML-236B?
Answer: Penicillium citrinum

Question: What was discovered in long term studies?
Answer: too toxic for human use

Question: In what year was mevastatin discovered?
Answer: 1971

Question: Who discovered mevastatin?
Answer: Akira Endo

Question: What organism produces mevastatin?
Answer: Penicillium citrinum

Question: What enzyme helps produce cholesterol?
Answer: HMG-CoA reductase

Question: Why was Penicillium never marketed?
Answer: Unanswerable

Question: Who discovered Penicillium?
Answer: Unanswerable

Question: What is Penicillium responsible for producing?
Answer: Unanswerable

Question: What was discovered in short term studies?
Answer: Unanswerable

Question: In what year was Penicillium discovered?
Answer: Unanswerable